@article {Kharitonovae002785, author = {Tatiana Kharitonova and Yury G Shvarts and Andrey F Verbovoy and Natalia S Orlova and Valentina P Puzyreva and Igor A Strokov}, title = {Efficacy and safety of the combined metabolic medication, containing inosine, nicotinamide, riboflavin and succinic acid, for the treatment of diabetic neuropathy: a multicenter randomized, double-blind, placebo-controlled parallel group clinical trial ({\textellipsis}}, volume = {10}, number = {3}, elocation-id = {e002785}, year = {2022}, doi = {10.1136/bmjdrc-2022-002785}, publisher = {BMJ Specialist Journals}, abstract = {Introduction Antioxidants may have positive impact on diabetic polyneuropathy (DPN), presumably due to alleviation of oxidative stress. We aimed to evaluate the efficacy and safety of combination of antioxidants: succinic acid, inosine, nicotinamide, and riboflavin (SINR) in the treatment of DPN.Research design and methods In a double-blind, placebo-controlled clinical trial, men and women aged 45{\textendash}74 years with type 2 diabetes and symptomatic DPN, with initial Total Symptom Score (TSS) ˃5, were randomized into experimental (n=109) or placebo (n=107) group. Patients received study medication/placebo intravenously for 10 days, followed by oral administration for 75 days. Statistical significance was defined as a two-tailed p\<0.05.Results In SINR group, mean TSS change after 12 weeks was {\textendash}2.65 ({\textpm}1.46) vs {\textendash}1.73 ({\textpm}1.51) in the placebo group (p\<0.0001; t-test). Reduction of symptoms in the SINR group was achieved regardless of hemoglobin A1c levels, but better results were observed in patients with initial TSS \<7.5. The analysis of TSS subscores revealed statistically significant between-group differences by dynamics of the intensity of paresthesia and of numbness starting from day 11 (p=0.035 and p=0.001, respectively; mixed model); by day 57, statistically significant between-group differences were detected also by dynamics of burning intensity (p=0.005; mixed model). Study limitations are small effect size, moderate proportion of patients with severe DPN symptoms, subjective assessment of outcomes, exclusion of participants who received injectable glucose-lowering medications other than insulins, and patients with uncontrolled and type 1 diabetes.Conclusions The combination of SINR effectively alleviates DPN symptoms in patients with type 2 diabetes.Trial registration number ClinicalTrials.gov Registry (NCT04649203; Unique Protocol ID: CTF-III-DM-2019).Data may be obtained from a third party and are not publicly available. Data were collected and stored by an independent CRO.}, URL = {https://drc.bmj.com/content/10/3/e002785}, eprint = {https://drc.bmj.com/content/10/3/e002785.full.pdf}, journal = {BMJ Open Diabetes Research and Care} }